Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
209lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
12 lessons
8mResearchAdvanced
Retatrutide TRIUMPH-1 Phase 3 Results: How to Track the 28.3% Weight Loss Data
The new TRIUMPH-1 readout gives retatrutide users a clearer dose-response map: 4 mg, 9 mg, and 12 mg all worked, but the tolerability tradeoffs matter.
7mPeptidesIntermediate
MOTS-c and NAD+: The Mitochondrial Longevity Pair Gaining Serious Scientific Attention
MOTS-c is a peptide encoded in your mitochondrial DNA that declines with age and mimics exercise benefits in animal studies. NAD+ has actual human clinical data. Here's what 2026 research shows about why these two molecules may work together — and what's still missing.
8mPeptidesIntermediate
Epithalon (Epitalon): The Longevity Peptide That May Extend Your Telomeres
Epithalon is one of the most researched longevity peptides in existence, with decades of clinical data behind it. This guide covers the science of telomere elongation, dosing options, cycling protocols, and how it fits into a modern anti-aging stack.
11mPeptidesIntermediate
Why Retatrutide is Winning: Clinical Data Shows 28% Superior Fat Loss Over GLP-1
A 2026 meta-analysis comparing retatrutide to GLP-1 (Ozempic/Wegovy) and tirzepatide shows retatrutide delivers 28% superior fat loss. Here's the science behind why the triple-agonist approach is reshaping weight loss and body recomposition.
9mResearchAdvanced
Retatrutide TRIUMPH-4 Phase 3 Trial: 28.7% Body Weight Reduction Confirmed
Phase 3 data is in: retatrutide produced an average 28.7% body weight reduction — roughly 71 lbs — in the TRIUMPH-4 trial. Here's what the numbers mean and how the triple agonist mechanism drives these results.
10mPeptidesIntermediate
TB-500 and Cardiac Recovery: What the 2026 Human Trial Data Shows
TB-500 has moved from rodent models to human cardiac recovery trials. The 2026 data is early, but the mechanism and results are worth understanding — especially if you're using TB-500 for recovery.
11mPeptidesIntermediate
BPC-157: The Peptide That Regenerates Tissue—Science, Clinical Evidence, and Real Results
BPC-157 activates multiple tissue repair pathways simultaneously. Users report faster recovery from injury, improved gut healing, enhanced joint mobility—backed by published clinical data.
10mResearchAdvanced
Retatrutide TRANSCEND Trial: What the Phase 3 Data Actually Shows
TRANSCEND confirmed retatrutide as the most effective GLP-1 class compound tested in late-stage trials. 16.8% mean body weight reduction and a 2.0-point A1C drop in 40 weeks — here's what the full data shows.
12mPeptidesIntermediate
Retatrutide vs Tirzepatide: What the Latest Clinical Data Shows
Retatrutide and tirzepatide dominate the peptide conversation, but they're not interchangeable. Here's what the latest clinical research reveals about their differences, efficacy, and mechanisms.
8mPeptidesIntermediate
Retatrutide Phase 3 Results: What the Clinical Data Tells Us
New Phase 3 data shows retatrutide delivering superior metabolic benefits. Here's what researchers found and why it matters.
10mPeptidesIntermediate
Retatrutide Shows 23% Superior Weight Loss vs Tirzepatide in Phase 3 Trial
Retatrutide, the triple-action GLP-1/GIP/glucagon receptor agonist, outperforms tirzepatide by 23% in the latest human clinical trial—the most comprehensive weight loss comparison to date.
10mPeptidesIntermediate
Peptide Research Breakthroughs in 2026: What Clinical Trials Show
2026 marks a pivotal year for peptide research. Here's what the latest clinical data reveals about the most promising peptide candidates and their real-world applications.
Also available at /blog for legacy links.